4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,953,037 | +163.7% | 153,420 | +274.3% | 0.00% | – |
| Q2 2023 | $740,599 | +85.9% | 40,985 | +76.9% | 0.00% | – |
| Q1 2023 | $398,327 | -37.5% | 23,172 | -19.3% | 0.00% | – |
| Q4 2022 | $637,427 | -62.6% | 28,700 | -86.5% | 0.00% | – |
| Q3 2022 | $1,703,000 | -27.7% | 211,859 | -37.3% | 0.00% | – |
| Q2 2022 | $2,357,000 | +23.9% | 337,742 | +168.4% | 0.00% | – |
| Q1 2022 | $1,902,000 | +107.9% | 125,833 | +201.9% | 0.00% | – |
| Q4 2021 | $915,000 | +145.3% | 41,677 | +201.2% | 0.00% | – |
| Q3 2021 | $373,000 | -43.3% | 13,836 | -49.3% | 0.00% | – |
| Q2 2021 | $658,000 | -22.7% | 27,312 | +39.2% | 0.00% | – |
| Q1 2021 | $851,000 | -60.9% | 19,616 | -62.6% | 0.00% | -100.0% |
| Q4 2020 | $2,175,000 | – | 52,463 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |